(Q80442184)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15306835%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

review article

1 reference

title

Insulin detemir: improving the predictability of glycaemic control (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15306835%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

D Russell-Jones

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15306835%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

publication date

1 September 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15306835%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

28 Suppl 2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15306835%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

S29-34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15306835%20AND%20SRC:MED&resulttype=core&format=json

The reality of glycaemic control in insulin treated diabetes: defining the clinical challenges

31 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802747

7 January 2021

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802747

7 January 2021

The action profiles of human NPH insulin preparations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802747

7 January 2021

Establishment of time-action profiles for regular and NPH insulin using pharmacodynamic modeling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802747

7 January 2021

Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802747

7 January 2021

Limitations to subcutaneous insulin administration in type 1 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802747

7 January 2021

Variability of insulin absorption and insulin action

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802747

7 January 2021

Variation in125i-insulin absorption and blood glucose concentration

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802747

7 January 2021

Absorption of isophane (NPH) insulin and its clinical implications.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802747

7 January 2021

Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802747

7 January 2021

Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802747

7 January 2021

Insulin Detemir Is Characterized by a Consistent Pharmacokinetic Profile Across Age-Groups in Children, Adolescents, and Adults With Type 1 Diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802747

7 January 2021

Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802747

7 January 2021

Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802747

7 January 2021

Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802747

7 January 2021

Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802747

7 January 2021

Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802747

7 January 2021

Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802747

7 January 2021

Can we reduce hypoglycaemia with insulin detemir?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802747

7 January 2021

At last, a weight neutral insulin?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802747

7 January 2021

Identifiers

DOI

10.1038/SJ.IJO.0802747

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15306835%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference